Aptahem enter cooperation agreement with leading research institute in hematology

Aptahem announce they have entered a cooperation agreement with the Institute of Hematology and Blood Transfusion in Warsaw (IHIT), to identify APTA-1’s inhibitory mechanisms in the coagulation system.
IHIT is Poland’s most prestigious hematology research institute and reference hospital.

IHIT’s Professor Jerzy Windyga, a board member of the World Federation of Hemophilia (WFH), has expressed his personal interest in APTA-1 and will be Aptahem’s collaborator at IHIT. The studies with APTA-1 are expected to provide the scientific information needed to enable clinical studies to begin.

Michael Lindstam, CEO of Aptahem, has emphasized the importance of this cooperation, as IHIT have both the intellectual and physical resources to implement a comprehensive program of study. The potential to run future clinical trials at IHIT is also supported by this partnership.

For further information, contact:
Michael Lindstam, CEO Aptahem AB
Tel: 0766-33 36 99
E-mail: ml@aptahem.com

About Aptahem
Aptahem is developing drug candidates for the treatment and prevention of diseases caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke, and heart failure. Thrombosis, also called clot, is the medical term for an increased and unhealthy coagulation of blood cells that cause more than 30 percent of all deaths worldwide. Thrombosis occurs either through genetic inheritance or by thrombosis occurs in conjunction with surgery, trauma, due to medication or by the victim suffering from a disease such as cancer. The company holds patents for Europe, China, the United States and Canada and the patent application in India.

Forward-looking statements
This communication contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as well as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.